MIST News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MI

Mkt Cap

$88.0M

Volume

962.23K

Next Earnings

November 11th

Loading chart

MI

MISTMilestone Pharmaceuticals Inc. Common Shares

MIST

Pay with—

Available Balance0.00

MI

Mkt Cap

$98.9M

Volume

962.23K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Milestone Pharmaceuticals Inc. granted 288,000 stock options to six new employees as a material inducement for hiring. The options have an exercise price of $1.32 per share and vest over four years, with 25% vesting after one year followed by monthly installments. The grants were made under the company's 2021 Inducement Plan in compliance with Nasdaq regulations.GlobeNewswire Inc. · Jul 3, 2026

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVTMilestone Pharmaceuticals announced the RESET-PSVT registry, a Phase 4 observational study designed to generate real-world evidence on CARDAMYST (etripamil) nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. The study, led by Duke Clinical Research Institute, will enroll approximately 450 patients across 20 sites beginning by end of 2026. CARDAMYST was FDA-approved in December 2025 and is now commercially available.GlobeNewswire Inc. · Apr 10, 2026

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)Milestone Pharmaceuticals received FDA approval for CARDAMYST, the first self-administered nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults, offering a novel at-home treatment option for over 2 million Americans with this heart condition.GlobeNewswire Inc. · Dec 13, 2025

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025Milestone Pharmaceuticals presented clinical trial data for etripamil nasal spray, showing consistent efficacy and safety in treating paroxysmal supraventricular tachycardia (PSVT) across multiple studies, with a New Drug Application currently under FDA review.GlobeNewswire Inc. · Nov 3, 2025

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025Milestone Pharmaceuticals will present research data on etripamil, a potential treatment for paroxysmal supraventricular tachycardia, at the American Heart Association Scientific Sessions in New Orleans in November 2025.GlobeNewswire Inc. · Oct 9, 2025

Atrial Fibrillation (AF) Pipeline Market Research Report 2025 | Insights on 10+ Companies and 12+ Drugs in the Pipeline LandscapeA comprehensive market research report analyzing the Atrial Fibrillation pipeline, covering over 10 companies and 12+ pipeline drugs, highlighting emerging treatments, clinical trials, and key developments in managing cardiac arrhythmia.GlobeNewswire Inc. · Jul 25, 2025

Milestone Pharmaceuticals Announces Proposed Public OfferingMilestone Pharmaceuticals has initiated an underwritten public offering of common shares and warrants to raise funds for clinical development and commercial launch of etripamil, a treatment for paroxysmal supraventricular tachycardia (PSVT).Benzinga · Jul 11, 2025

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal SprayMilestone Pharmaceuticals received FDA acceptance for its response to a Complete Response Letter for CARDAMYST (etripamil) nasal spray, with a new PDUFA action date of December 13, 2025. The company also extended its $75 million Royalty Purchase Agreement with RTW Investments until December 31, 2025.GlobeNewswire Inc. · Jul 11, 2025

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in ChinaMilestone Pharmaceuticals' licensing partner Ji Xing Pharmaceuticals announced positive results from a Phase 3 trial of etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) in China. The trial met its primary endpoint, with a significantly greater proportion of patients treated with etripamil converting from PSVT to sinus rhythm within 30 minutes compared to placebo.GlobeNewswire Inc. · Sep 6, 2024

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of DirectorsMilestone Pharmaceuticals announced the appointment of Joseph Papa, a renowned pharmaceutical and healthcare leader, to its Board of Directors. Papa's extensive experience in the industry is expected to provide strategic guidance as Milestone prepares for the potential approval of its investigational drug CARDAMYST for the treatment of paroxysmal supraventricular tachycardia.GlobeNewswire Inc. · Sep 4, 2024

to start trading

MI

MISTMilestone Pharmaceuticals Inc. Common Shares

MIST

Pay with—

Available Balance0.00

Your PositionYou don't own any MIST yet.

Related Tickers

Earnings